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Structural magnetic resonance imaging (sMRI) studies have frequently demonstrated that 
neuroanatomical abnormalities are already present at the point that first-episode of psychosis (FEP) is 
identified (Dazzan et al. 2012; Olabi et al. 2011). The initial phase of psychotic illness may represent a 
particularly vulnerable time for progression of neuroanatomical abnormalities (Cahn et al. 2002; 
Andreasen et al. 2011) with suggestions of a potential plateau effect on progression of grey matter 
(GM) deficits across the brain in longitudinal studies of more established schizophrenia (Hulshoff Pol 
and Kahn, 2008; van Haren et al. 2012). The most consistent neuroanatomical changes seen in 
longitudinal studies of FEP relate to progressive lateral ventricular (LV) enlargement (Kempton et al. 
2010; Olabi et al. 2011), and reduction in total GM volume (Olabi et al. 2011; Gutierrez-Galve et al. 
2014). 
 
Progressive morphometric abnormalities such as reduction in deep GM volume and cortical thinning 
in the initial years after the onset of psychotic illness may be inherent to the pathogenesis of 
psychosis and/or related to other factors including cumulative antipsychotic medication usage (Ho et 
al. 2011; Vita et al. 2012), genetic susceptibility (Andreassen et al. 2013; Vazquez-Bourgon et al. 2016) 
and cannabis use (Rais et al. 2008). In contrast to the ventricular and whole-brain cortical GM 
findings, reports of progressive change in subcortical volumes and regional cortical thickness have 
been inconsistent (see Table 1 for a summary of longitudinal studies to-date). A meta-analysis of 
longitudinal MRI studies of first episode schizophrenia patients showed a significant pattern of 
progressive GM tissue loss in the frontal, temporal, parietal lobes and in the Heschl’s gyrus relative to 
healthy controls (HCs) (Vita et al. 2012). Additionally, several other studies have demonstrated 
increased global cortical thinning, particularly pronounced in the frontal cortex (Roiz-Santianez et al. 
2014; Guo et al. 2015) with significant tissue loss in the frontal, temporal and parietal cortices of FEP 
patients compared to HCs over time (de Castro-Manglano et al. 2011). However, this remains an 
inconsistent finding with other studies demonstrating no such changes (Dickey et al. 2004; Haukvik et 
al. 2016). 
These inconsistencies regarding neuroanatomical progression after FEP may be due to embedded 
study heterogeneities of a clinical (including variable clinical severity, antipsychotic medication use 
and follow-up periods) and methodological (including different image acquisition and analysis 
techniques) nature.  
The current, naturalistic, longitudinal study aims to overcome these issues in order to determine 




over a 3-year follow-up period in FEP patients who underwent MRI scanning very shortly after 
presentation to mental health services. It also aims to ascertain whether any neuroanatomical 
changes were related to particular clinical variables including symptom severity, cumulative dose of 
antipsychotic medications and level of functioning. We hypothesised that, compared with HCs, 
individuals with FEP would demonstrate greater ventricular enlargement, increased cortical thinning 
and reduction in the volume of subcortical GM structures over time. We also hypothesised that 
progressive changes would be associated with measures of poorer outcome including decreased 
functioning, more negative symptoms and greater use of antipsychotic medication in patients. 
 
2 Methods 
2.1 Study design and setting 
Participants were included if they had previously participated in the initial phase of this study (Scanlon 
et al. 2014) and had no contraindications to MRI procedures. Exclusion criteria for all participants 
included a history of neurological disorders, intellectual disability, life-time substance dependency (as 
defined by DSM-IV-TR), a history of head injury resulting in loss of consciousness for over 5 minutes 
and oral steroid use in the past 3 months. HCs were excluded if they had a personal or family history 
of any psychotic illness. Written informed consent was provided by all participants at both time-points 
and ethical approval was obtained from the National University of Ireland Galway and Galway 
University Hospitals Research Ethics Committees. 
 
2.2 Participants  
Participants were recruited from the Galway University Hospital and the Mental Health Services 
within the West of Ireland. The original baseline sample comprised 46 patients presenting with FEP 
(defined as having at least one psychotic symptom) and 46 controls (Scanlon et al. 2014). Patients 
underwent MRI scanning as soon as feasible after presentation and within 8 weeks of commencing 
antipsychotic medication (the median duration of treatment was 14 days).  Re-recruitment of all 
original participants was attempted.  Five patients from the original patient cohort were un-
contactable and 13 refused to participate. Two healthy volunteers were later excluded as imaging 
data was acquired on a different MRI scanner, while others within this cohort were un-contactable 
(n=4) or declined our invitation to participate (n=12). Thus, at follow-up the final successful re-
recruitment rate was 61%, with 28 FEP individuals and 28 HCs re-recruited to the current longitudinal 




dose prescribed at baseline in patients from the original cohort who were successfully re-recruited at 
follow-up (n=28) compared to those not re-recruited (n=18).  
 
2.3 Clinical assessment 
The baseline clinical assessments were described previously in detail (Scanlon et al. 2014) and were 
repeated at follow-up. Briefly, the Structured Clinical Interview (SCID) for DSM-IV Research Version 
(First et al. 2002) was repeated to establish updated diagnostic status given its potential variation 
(Fusar-Poli et al. 2016). As previously (Kenney et al. 2015), schizophrenia, schizoaffective disorder, 
psychotic disorder not otherwise specified (NOS), substance induced psychosis and delusional 
disorder were defined as non-affective types of psychoses (n=16) whereas bipolar I disorder and 
major depressive disorder were defined as affective types of psychoses (n=12) for further subcategory 
analyses in patients. Ratings of symptomatology and functioning were carried out using the Positive 
and Negative Syndrome Scale (PANSS: 0–6 scale) (Kay et al. 1987) and the Global Assessment of 
Functioning score (GAF) (Hall, 1995) respectively. HCs were also re-screened for the presence of 
psychotic illness using the SCID-NP (non-patient) edition (First et al. 2002). Total antipsychotic 
medication administered during the follow-up period was converted to chlorpromazine (CPZ) 
equivalents (Taylor et al. 2007; Woods, 2003) from detailed clinical interviews and review of clinical 
notes. Similarly, information on cannabis use was collected from clinical interviews and supplemented 
by a review of clinical notes and categorised via binary coding based on the adapted criteria of the 
Centre for Addiction and Mental Health (Boak et al. 2017) for either heavy use (≥ 12 times on a 
lifetime basis and at least once during the past year) or none/minimal use (0-11 times on a lifetime 
basis and none during the past year).  
 
2.4 MRI data acquisition and processing 
Identical MRI data acquisition protocols, on the same 1.5 Tesla Siemens Magnetom Symphony 
scanner (Erlangen, Germany), and identical image pre-processing approaches with non-parametric 
non-uniform intensity normalisation (N3) (Scanlon et al. 2015) were implemented at follow-up as at 
baseline. The longitudinal FreeSurfer processing pipeline (v.5.3.0, Reuter et al. 2012) was employed 
for segmentation of subcortical structures, ventricles and to examine the progression of cortical 
thickness changes over time. Detailed descriptions of the MRI image acquisition and processing 







2.5 Statistical analyses 
Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS, v.24.0) and 
the FreeSurfer statistical tools (QDEC®).  
The Kolmogorov-Smirnov test was used to examine the distribution of data for normality. Clinical and 
demographic differences between groups over time were assessed using chi-square or independent t-
test. Paired t-tests were used to assess longitudinal changes in clinical symptom and functionality 
scores within FEP individuals. The bilateral FreeSurfer segmented brain volumes of deep grey matter 
structures (i.e., caudate, putamen, globus pallidus, nucleus accumbens, thalamus, hippocampus, 
amygdala) and lateral ventricles were summed. Furthermore, changes in the third ventricle, total grey 
and white matter were investigated. In total, 11 regional volumes were examined, together with the 
manually segmented hippocampal volumes and are referred to as the region-of-interest (ROI).  
 
FreeSurfer automatically segments the brain based on a subject‐independent probabilistic atlas to 
provide subject‐specific measured values of both cortical and subcortical structures. However, this 
probabilistic atlas was created from a manually labelled training set which was mapped into Talairach 
space in which all the subjects’ images are registered to during the process of segmentation (Fischl 
et al. 2004). In an explorative cortical analysis where findings may span over portions of several atlas-
defined regions, this approach becomes less reliable at localising changes within specific lobular 
subregions (DeLisi, 2008). Thus, an analyses approach that examines thickness change at each vertex 
of the cortical surface is considered more appropriate for our explorative cortical analyses. 
The QDEC (Query, Design, Estimate, Contrast) is a single-binary application included in the FreeSurfer 
distribution which uses a vertex-wise approach to perform group averaging and inference on cortical 
morphometric data. Following the FreeSurfer recommendations 
(http://surfer.nmr.mgh.harvard.edu/) for a robust measure of cortical thickness change with 
increased statistical power, we used the vertex-wise linear regressions in the QDEC interface 
[longitudinal two-stage model (Reuter et al. 
2012;https://surfer.nmr.mgh.harvard.edu/fswiki/LongitudinalTwoStageModel)] for our hypothesis-
free investigation of the entire cortical mantle. However, we did not apply the vertex-wise approach 
for the investigations in relation to the subcortical and ventricular volumes because volumetric 
segmentation of this structures are not prone to the limitation described above, hence, a repeated-





2.6 Subcortical and ventricular volume analyses 
Repeated-measures analysis of co-variance (ANCOVA) with Greenhouse-Geisser corrections was used 
to investigate differences in the progression of regional morphometric abnormalities over the 3-year 
follow-up period. In each general linear model, the dependent measures were MRI volumes and the 
independent measure was group (FEP vs. HC) or (affective vs non-affective) in a patient subgroup 
comparison. The within-subject factor was time (baseline vs. follow-up) with hemisphere (left vs. 
right) added for bilateral structures. Given the potential of age, gender and intracranial volume (ICV) 
to confound results in brain morphometric investigations (Barnes et al. 2010), all analyses included 
these covariates. Where there were significant findings, further post-hoc within-group analyses of 
variances were conducted to identify the direction of lateralised effects. To better quantify the 
significant findings, effect sizes were calculated from the adjusted percent volume differences at 
baseline and follow-up for each region of interest (ROI). Given the relatively small sample size, 
Hedges’ g was adopted (Hedges and Olkin, 1985) for unbiased effect sizes (Calin-Jageman, 2018) (See 
Table 2 Legend). The adjusted (for age, gender and ICV) percent volume difference (pvd) of each ROI 
was computed as:  
pvd = 100 x [(adjusted vol. at follow-up – adjusted vol. at baseline)/adjusted vol. at baseline] eqn (1) 
 
2.7 Cortical thickness analyses 
In QDEC®, global longitudinal vertex-wise linear regressions were conducted to determine the effect 
of diagnosis on the dependent variable of symmetrised percent thickness change (spc) (% per year) 
across the cortical mantle while controlling for age at baseline. Scan interval was not included in the 
rate of change model as it was already accounted for in the calculation of the dependent variable. 
Furthermore, spc does not depend on intracranial volume, and is less dependent on baseline values 
than measures such as percent change (Berry and Ayers, 2001). For the group effect of diagnosis on 
progressive cortical thickness change, participants were contrasted as FEP patients and HCs. The 
Monte Carlo null-z strategy which employs 10000 vertex-wise iterations was implemented (Hagler et 
al. 2006), with an initial cluster‐forming threshold of p<0.05 for multiple comparisons to reduce the 
probability of type I errors. The identified clusters were extracted and averaged for further analyses. 
We conducted independent ANCOVAs to compute group (FEP vs HCs) and subgroup (affective vs non-
affective vs HCs) comparisons over the extracted ROI cortical thickness of change measure (spc).  
 
2.8 Correlation analyses 
For brain regions demonstrating significant progressive volume and rates of cortical thickness change 




used to determine the strength of potential associations between percent volume/rate of thickness 
change in ROI and change (Time2 - Time1) in clinical or functional variables. A two-tailed α level of 0.05 
was used for statistical testing. Given that brain structures are not independent (Haukvik et al. 2016) 
and our study was being driven by a priori hypotheses of progressive brain change, we did not apply a 
Bonferroni correction for these group analyses, as per similar previous studies (Ayesa-Arriola et al. 
2013; Roiz-Santiánez et al. 2014).  
3 Results 
3.1 Clinico-demographic characteristics 
Demographic and clinical data are presented in Table 3. It proved more challenging to re-recruit 
younger controls from the original sample, and individuals with FEP were significantly younger than 
HCs in this longitudinal phase of the study (t (54) = -2.07, p = 0.04). They had also engaged in less years 
of education (t (54) = -2.37, p = 0.02). There were no differences between the groups in gender 
distribution or time between scans. Formal SCID diagnoses of the patients at follow up were: 
schizophrenia (n=8), bipolar I disorder (n=9), major depressive disorder (n=3), schizoaffective disorder 
(n=3), psychotic disorder not otherwise specified (NOS) (n=3), delusional disorder (n=1) and substance 
induced psychotic disorder (n=1). At baseline, 24 patients were taking second-generation 
antipsychotic (SGA) medication, 1 was taking a first-generation antipsychotic (FGA) medication and 3 
participants were not taking antipsychotic medication. At follow-up, 16 individuals were treated with 
SGAs comprising olanzapine (n=6), aripiprazole (n=5), risperidone (n=3), clozapine (n=2), quetiapine 
(n=2), amisulpride (n=1) and no patients were treated with a FGA medication. Three individuals were 
treated with more than one SGA. In addition to a SGA, 7 patients were prescribed antidepressants 
and 4 patients were prescribed mood stabilisers. Nine patients were on no psychotropic medications 
at follow-up. Within the patient group, there were significant reductions in positive (t(27) = 5.41, 
p<0.001) and general psychopathology (t(27) =3.89, p<0.001) subscale symptoms of the PANSS 
between baseline and follow-up, with a reduction in negative symptoms also demonstrated, that did 
not reach statistical significance (t(27) =1.92, p=0.07). GAF scores increased significantly (t(27) = -7.87, 
p<0.001) between baseline and follow-up assessments (Table 3). 
 
3.2 Group comparison of progressive subcortical and ventricular changes over time 
As demonstrated in Table 2 and Figure 1, significant group x time interactions were found, indicating 
progressively greater volume reduction of the caudate [F(1,51)=5.86, p=0.02, Hedges’ g=0.66], 
putamen [F(1,51)=6.06, p=0.02, g=0.67] and thalamus [F(1,51)=6.99, p=0.01, g=0.72] in FEP patients 




patients [F(1,51)=3.37, p=0.07, g=0.50]. A significant effect of group x time x laterality [F(1,51)=4.38, 
p=0.04, g=0.57] was demonstrated for LV enlargement in patients compared to controls. Post-hoc 
analysis demonstrated significant right LV enlargement over time in patients compared to controls 
[F(1,51)=4.03, p=0.05)] which was not significant for left LV enlargement [F(1,51)=2.66, p=0.11)]. 
Further patient subgroup comparisons (affective versus non-affective) for longitudinal changes 
showed no significant volume differences (see Table S4) in subcortical and ventricular findings, 
however, we remain potentially underpowered to detect such a difference. 
Given the potential effects of covariates which differ between groups (Miller and Chapman, 2001), we 
also ran a number of confirmatory analyses, showing that these findings were essentially unaltered 
when age was removed as a covariate and when scan interval time was added as a covariate in all 
analyses, indicating that our results are unlikely to be driven by these factors. There were no 
progressive volume deficits identified in medial temporal lobe structures, including the hippocampus 
which was manually segmented as previously (Akudjedu et al. 2018). 
 
3.3 Group comparison of rates of progressive cortical brain change overtime 
Increased rates of progressive cortical thinning were observed in FEP patients relative to HCs, mostly 
in the left frontal and temporal regions. Specifically, significant clusters were observed in the regions 
of the left lateral orbitofrontal cortex, superiorparietal, lingual, and superiortemporal gyrus, the banks 
of the superior temporal sulcus, fusiform gyrus and the bilateral superiorfrontal gyrus (Fig. S1 and 
Table S2, all uncorrected, p<0.05). There were no regions of cortical thickening over time in patients 
compared with controls. After correction for multiple comparisons, a cluster of progressive cortical 
thinning was observed [Fig. 2, all corrected p<0.05] in FEP patients at the left lateral orbitofrontal 
cortex extending into aspects of the left pars orbitalis, pars triangularis, rostral middle frontal gyrus 
and frontal pole.  A significantly reduced spc [F(1,52)=5.11, p=0.03)] in individuals with FEP relative to 
HCs, with a mean difference of 0.84% [95% CI (0.10, 1.59)] (Fig. S2A) over the 3-year period was 
demonstrated for this left lateral orbitofrontal region (LLOFR). On patient subgroup analysis, there 
was a trend towards significance for progressive thinning [F(2,51)=2.87, p=0.07)] in the LLOFR. 
Compared to controls, there was a significant mean regional thinning difference of 1.01% [95% CI 
(0.15, 1.86), p=0.02] in the non-affective subgroup and a non-significant thinning of 0.58%/year [95% 
CI (-0.42, 1.58), p=0.25] in the affective subgroup (Fig. S2B). Further pairwise comparisons showed no 
significant mean difference [0.43%, 95 CI (-0.63, 1.48), p=0.42] in cortical thickness of this ROI 
between the affective and non-affective subgroups (Fig. S2B). The main group differences remained 





3.4 Association of progressive neuroanatomical changes with change in clinical and functional 
variables 
Table S3 displays the partial correlation coefficients of clinical and functional measures assessed with 
and change in volume of the regions-of-interest and spc of the LLOFR in FEP patients. A greater 
reduction of putamen (r=0.49, p=0.01; Fig. S4A) and globus pallidum volume (r=0.44, p=0.03) was 
associated with lower cumulative antipsychotic medication over the 3-year follow-up period. 
Increased right LV (r=0.43, p=0.03), total LV (r=0.41, p=0.04; Fig. S4B) and 3rd ventricular (r=0.55, 
p=0.004) volume over time was associated with worsening negative symptoms on the PANSS. 
Additionally, increased right LV (r=-0.43, p=0.03), total LV (r=0.41, p=0.04; Fig. S4C) and 3rd ventricular 
(r=-0.49, p=0.01) volume over time was associated with reduced GAF scores. A moderate correlation 
between antipsychotic medication use and total GM loss over time was also found (r=-0.45, p=0.02). 
Furthermore, the ventricular enlargement over time was associated with thalamic and striatal 
reduction but not with cortical thinning (Table S3 and Fig.S5). Cortical thinning in the LLOFR was not 
associated with changes in clinical or functional measures over time. 
 
4 Discussion 
Our results indicate that there is regionally specific progression of neuroanatomical deficits amongst 
patients in the years after their first-episode of psychosis. These deficits are characterised by a 
relatively greater volume reduction in the dorsal striatal and thalamic regions, by right lateral 
ventricular enlargement and by a greater progressive rate for cortical thinning of the LLOFR in FEP 
patients relative to HCs. In contrast, there was relative preservation of other regions, and in particular 
of the medial temporal lobe structures. Additionally, the progressive changes in LV volume were 
associated with indices of poorer outcome amongst patients, as evidenced by worsening negative 
symptoms and functioning scores over 3-years.  
 
4.1 Progressive subcortical and ventricular changes 
Striatal volume reductions over time have been reported in some previous studies of FEP patients 
(Theberge et al. 2007; Boonstra et al. 2011) and at-risk-mental state (ARMS) patients who were 
treatment naive (Smieskova at al. 2013). However, other studies have reported increased putaminal 
and caudate volume (Massana et al. 2005; Glenthoj et al. 2007; Roiz-Santiánez et al. 2014) or no 
significant volumetric differences between FEP patients and HCs (Lang et al. 2001; Haukvik et al. 
2016) (see Table 1). Long exposure to antipsychotic medications has also been linked to increased 
striatal volume (Okugawa et al. 2007; van Haren et al. 2007). Other longitudinal studies examining 




with antipsychotic medication (Smieskova at al. 2013; Katagiri et al. 2019). Thus, the use of 
antipsychotic medication in some cohorts may be obscuring basal ganglia reduction which is more 
readily detected in medication naïve sample or in those with minimal medication exposure, as in this 
study. Here, patients were minimally medicated (<3 weeks) prior to their baseline scan, and only 57% 
were treated with SGAs at the time of follow-up MRI scan (none with FGAs). In further support of this 
interpretation, high cumulative antipsychotic medication during the interscan period was correlated 
with increased putaminal and pallidal volumes over time.  
 
The progressive thalamic volume reduction observed in this study is consistent with some longitudinal 
studies of FEP (Theberge et al. 2007; Andreasen et al. 2011) and established psychosis (van Haren et 
al. 2007; Cobia et al. 2017). Moreover, reduced thalamic volume has also been observed over time in 
ARMS patients (Harrisberger et al. 2016) and in those at high genetic liability for schizophrenia (Lawrie 
et al. 2001; McDonald et al. 2004). Others have reported increased thalamic volume after a short 
period of antipsychotic treatment (Deng et al. 2009; Dazzan et al. 2005) and no significant thalamic 
changes were observed in an adolescent cohort after a 3-year follow-up (de Castro-Manglano et al. 
2011). In the current study, progressive thalamic volume reductions were not associated with any 
measurements of clinical outcome; however, other measurements of functional and cognitive 
performance were not assessed. 
 
While total LV change is not statistically significant in this study, a pattern of progressive increase of 
right LV volume over time with medium effect size in FEP patients compared to controls is consistent 
with a number of previous longitudinal studies (Cahn et al. 2002; Andreasen et al. 2011; Suárez-Pinilla 
et al. 2015). However, other studies failed to demonstrate significant LV enlargement over time (Puri 
et al. 2001; Nakamura et al. 2007; Boonstra et al. 2011) potentially due to its highly variable structure. 
Our findings further indicate that the neuroprogressive process of LVs in poor clinical outcome 
patients, possibly relates to the observed regionally specific shrinkage of adjacent (thalamus and 
caudate) and remote (putamen) subcortical GM structures over time, considering the significant 
association between LVs and these subcortical structures. These findings are consistent with Gaser 
and colleagues (2004) who reported similar associations between ventricular enlargement and 
volume reductions of the thalamus, striatum and the superior temporal cortex in a schizophrenia 
cohort. Thus, these associations suggest that such volumetric progression could potentially be viewed 
as a biomarker of poor outcome in the illness. Additionally, LV enlargement over time has previously 
been associated with poorer clinical outcomes in a number of previous studies (Lieberman et al. 2001; 





4.2 Progressive cortical changes 
Cortical thinning was identified most prominently in the left prefrontal region of the brain after the 
first 3-years of FEP. With this finding consistent with other studies in FEP patients (Andreasen et al. 
2011; Buchy et al. 2017), ARMS patients (Cannon et al. 2015) and in individuals with established 
schizophrenia (van Haren et al. 2011; Cobia et al. 2012). Of note, cortical thinning was present in this 
broad and typical sample of patients after their FEP covering a range of psychotic diagnoses and with 
variable clinical outcomes with a substantial proportion of the cohort not taking antipsychotic 
medication at follow-up. Indeed, we found similar rates of cortical thinning in affective and non-
affective psychosis. In contrast, no significant cortical thinning in some other heterogenous FEP 
samples were detected (Haukvik et al. 2016; Palaniyappan et al. 2019), however this inconsistency 
may be related to a relatively short follow-up period (1 year, Haukvik et al. 2016) or small sample size 
(n=18, Palaniyappan et al. 2019) in these studies. 
Progression of cortical deficits in the years after FEP is considered a major neurobiological trait of 
psychotic illness (Cobia et al. 2012); however, the specific mechanisms underlying progressive loss of 
frontal lobe thickness still remain unclear. Some evidence suggests neuropil pruning as a potential 
cause of progressive reduction of grey matter in schizophrenia (Selemon and Goldman-Rakic, 1999) 
resulting in a distributed cortical reorganisation mostly leading to synaptic dysfunction in response to 
psychosis (Palaniyappan et al. 2018). Thus, our reported pattern of progressive change may suggest 
an active but inefficient cortical reorganisation which is likely initiated from the left prefrontal cortex 
in the early years after FEP with further progression to other cortices across the entire course of 
illness (van Haren et al. 2011).  
 
4.3 Associations of progressive neuroanatomical change 
Although the identified volume reduction of subcortical structures were not significantly associated 
with cortical deficits and LV enlargement in the same FEP patients, the observed changes in these 
structures potentially indicate an early emergence of an aberrant functional coupling in 
neuroanatomy after FEP (Steullet, 2019), with a diffusion imaging study observing microstructural 
alterations in the mediodorsal and pulvinar regions of the thalamus, that directly connected to the 
orbitofrontal, latero-temporal cortices and basal ganglia (Cho et al. 2019). Furthermore, the observed 
poor association of cortical deficits with volume reduction in the dorsal striatum may be related to a 
subregional striatal response to antipsychotic medication (Massana et al. 2005; Roiz-Santiánez et al. 




cortical thinning of the LLOFR, which is consistent with studies in both FEP (Gutiérrez-Galve et al. 
2015) and in established schizophrenia (Cobia et al. 2012), suggesting that regional cortical thinning is 
an inherent feature of progressive psychotic illness (Nesvag et al. 2008) and may reflect an underlying 
neuropathophysiological process associated with psychosis onset.   
 
4.4 Anatomically preserved regions  
There was relative anatomical preservation of medial temporal lobe volume and global brain tissues 
observed in this study, a finding concordant with some other studies (Schaufelberger et al. 2011; 
Wood et al. 2001; Asami et al. 2012). These may be a potential characteristic feature of the initial 
stages of psychosis (Zipursky et al. 2004). While the FreeSurfer-derived hippocampal volumes were 
larger than manually-segmented volumes, comparable case-control differences were found with both 
approaches, indicating that this finding does not relate to methodological bias. Interestingly, there 
was a moderate correlation at a statistical trend level between progressive volumetric deficit of 
manually segmented hippocampal volume and poorer clinical outcome, which was not evident in the 
larger FreeSurfer segmented structure. This may be because the manually segmented hippocampus 
focusses upon the functionally specific hippocampus proper and dentate; whereas FreeSurfer 
segmented hippocampus includes more functionally diverse structures, including variable amounts of 
subiculum and tail (Akudjedu et al. 2018). If confirmed in a larger sample, this would be consistent 
with the study of Lappin and colleagues (2014) that hippocampal volume enlargement after FEP is a 
marker of good clinical outcome. Similarly, total GM volume changes were associated with cumulative 
antipsychotic medication use, consistent with meta-analytical findings (Vita et al. 2015) of a significant 
association between progressive loss of cortical GM volume and cumulative antipsychotic intake.  
 
4.5 Strengths and limitations 
The main strength of the study is its application of a longitudinal design to a cohort of psychotic 
patients who were originally assessed shortly after presentation to the services and with minimal 
antipsychotic exposure. We were also able to employ the same scanner and acquisition sequences, 
without any major soft/hardware upgrades during the study period, and the participants were 
scanned in a random order at each time-point, thus minimising any acquisition bias due to changes in 
scanner characteristics over time, which is known to potentially confound group diagnostic 
differences. We used the longitudinal FreeSurfer pipeline, which has the advantage, compared to 
other analysis approaches, of accounting for inter-subject variability by creating an unbiased subject-
specific anatomical template (Reuter et al. 2010) from the images at both time-points, resulting in 




global longitudinal vertex-wise analyses approach, unlike the surface-based approaches which are less 
reliable at localising changes within specific lobular subregions (DeLisi, 2008; Cercignani et al. 2018), 
has enabled a hypothesis-free investigation over the entire cortical mantle. We recruited a broad 
psychosis phenotype for our study, rather than focus on non-affective disorders alone, which is more 
generally representative of FEP patients presenting to the services. Despite the potential increase in 
clinical heterogeneity associated with this approach, we were able to detect regions of sub/cortical 
progression and link these with measures of clinical outcome that were not confined to a non-
affective psychosis category. 
 
The main limitation of the study was the relatively small sample size and consequent risk of type II 
error and lack of generalisability of the results. We did not employ a stringent statistical approach to 
control for multiple comparisons as we sought a balance between type 1 and type 2 errors; none of 
the subcortical findings would survive stringent multiple testing correction, however our major 
findings were hypothesised in the direction found a priori based on current literature. Thus, these 
findings would benefit from replication in a larger sample. Furthermore, after repeating the cortical 
analyses using a cluster‐forming threshold of p<0.01, the main group difference remained significant 
(Fig. S3). Due to the limited data availability (functional measures but no childhood measures, 
cognition or physiological metrics), we were not able to assess in detail the contribution of other 
medications (e.g. mood stabilisers) and environmental exposures (e.g. childhood trauma, cannabis 
use) on the neuroanatomical measures acquired.  
4.6 Conclusion 
In conclusion, this study demonstrated the existence of localised progressive prefrontal cortical 
thinning, volume deficits in the dorsal striatum and thalamus, and right lateral ventricular 
enlargement over a 3-year period after patients first presented with psychotic illness. Taken together, 
these may be indicative of a progressive disturbance in the structural integrity of a subnetwork of the 
associative/cognitive component of the cortico-striato-thalamo-cortical circuitry involving the lateral 
orbitofrontal regions of the prefrontal cortex. This finding lends weight to the evidence that there is 
early regional neuroanatomical progression after FEP and thus such knowledge could potentially 
contribute to the identification of imaging biomarkers for psychosis which would be particularly 
beneficial in the critical early stages of the disorder. Future studies should also focus on 
comprehensively elucidating the functional consequences of anatomical progression by incorporating 
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